60度制药公司美国招股说明书（2026年3月13日版）

Up to $565,000 60 Degrees Pharmaceuticals, Inc. Common Stock This prospectus supplement (the “Prospectus Supplement”) amends and supplements the prospectus supplements dated each ofSeptember 5, 2025, March 2, 2026 and March 11, 2026, and the accompanying base prospectus dated July 18, 2024 (collectively, the“ATM Prospectus”), relating to the offer and sale of shares of our common stock from time to time pursuant to the terms of the AtThe Market Offering Agreement dated September 5, 2025 (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (the “SalesAgent”), acting as sales agent or principal. This Prospectus Supplement should be read in conjunction with the ATM Prospectus, and is We are filing this Prospectus Supplement to amend the ATM Prospectus to update the amount of shares of our common stock we mayoffer and sell to or through the Sales Agent pursuant to the Sales Agreement to $565,000.00, which gives effect to the 325,200 ofshares that were previously sold for aggregate gross proceeds of $980,510.52 pursuant to the Sales Agreement under the ATM As of the date of this Prospectus Supplement, our public float, which is equal to the aggregate market value of our outstanding votingand non-voting common stock, held by non-affiliates, was approximately $12,747,587, based on 2,472,949 outstanding shares ofcommon stock, of which approximately 2,451,459 shares were held by non-affiliates, and a closing sale price of our common stock of$5.20 per share on January 28, 2026. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities in a publicprimary offering under the registration statement of which this Prospectus Supplement and the ATM Prospectus forms a part with a On January 20, 2026, we effected a reverse stock split of our outstanding common stock at a ratio of one-for-four (1:4). All shareinformation presented in this Prospectus Supplement gives effect to this reverse stock split. Our common stock is listed on The Nasdaq Capital Market under the symbol “SXTP.” The last reported sale price of our commonstock on The Nasdaq Capital Market on March 12, 2026, was $2.91 per share. INVESTING IN OUR SECURITIES INVOLVES RISKS. SEE THE “RISK FACTORS” BEGINNING ON PAGE S-20 OFTHE ATM PROSPECTUS AND IN THE DOCUMENTS INCORPORATED BY REFERENCE IN THE REGISTRATION Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of thesesecurities or passed upon the adequacy or accuracy of this prospectus supplement and the accompanying prospectus. Anyrepresentation to the contrary is a criminal offense. H.C. Wainwright & Co. The date of this prospectus supplement is March 13, 2026